About Arcellx
Arcellx (NASDAQ:ACLX), is a dynamic player in the biotechnology sector focused on advancing innovative cell therapies for cancer and other life-threatening diseases. The company is dedicated to harnessing the power of CART-ddBCMA, their lead candidate, aiming to revolutionize treatment for multiple myeloma patients. Arcellx's projects span from research and development in cell-based immunotherapies to exploring novel platforms designed to better target and eliminate disease cells while minimizing side effects. At its core, Arcellx strives to push the boundaries of medical science to improve patient outcomes, establishing new standards in the field of advanced therapy medicinal products (ATMPs). Through its commitment to innovation, collaboration, and scientific excellence, Arcellx aims to deliver groundbreaking therapies that can offer hope and potentially curative options to patients in need.
Snapshot
Operations
Produtos e/ou serviços de Arcellx
- "CAR-T cell therapies targeting various cancers, including multiple myeloma, leveraging novel sparX proteins for improved control and flexibility."
- "Development of novel sparX proteins, engineered to bind specific antigens, paving the way for targeted, adaptable cancer treatments."
- "Pipeline of preclinical assets targeting solid tumors, aiming to expand the applicability of cell therapy beyond hematologic malignancies."
- "Proprietary platform for engineering T cells, enabling the production of more potent and specific cancer-fighting cells."
- "Collaborations with leading pharmaceutical companies to accelerate the development and commercialization of next-generation cell therapies."
- "Initiatives to improve manufacturing processes for cell therapies, enhancing scalability and accessibility for patients worldwide."
equipe executiva do Arcellx
- Mr. Rami ElghandourChairman of the Board, CEO & President
- Ms. Michelle Lim GilsonChief Financial Officer
- Dr. Christopher R. Heery M.D.Chief Medical Officer
- Ms. Aileen FernandesChief Operating Officer
- Mr. Narinderjeet Singh M.S.Chief Technical Officer
- Dr. Heba Nowyhed Ph.D.Chief Scientific Officer
- Ms. Myesha LacyChief Investor & Communications Officer
- Ms. Maryam Abdul-Kareem J.D., M.S.General Counsel & Chief Legal Officer
- Ms. Kate AikenChief People Officer
- Mr. Neeraj P. TeotiaChief Commercial Officer